Medtronic Unveils MiniMed Go™ System for Enhanced Diabetes Management in Europe

Innovative Diabetes Management: Medtronic Launches the MiniMed Go™ System in Europe

Medtronic Plc, a frontrunner in healthcare technology, expands its diabetes management solutions with the launch of the MiniMed Go™ Smart MDI system, paired with the Simplera™ sensor. The commercial rollout, which commences this month, marks a significant step forward in how individuals relying on multiple daily injections (MDI) manage their diabetes. By merging data from the InPen™ smart insulin pen and the Simplera™ sensor into a single mobile application, Medtronic offers a comprehensive tool designed to address the challenges faced by MDI users, including the management of insulin doses and real-time feedback.

The MiniMed Go™ system sets itself apart from traditional insulin delivery methods by providing enhanced features that prioritize user engagement and adherence. It empowers users with real-time personalized insights, automatic dose alerts, an advanced dose calculator, and ongoing support—all accessible through a smartphone app. This digital integration addresses a critical issue: the common problem of missed insulin doses, which can severely impair glycemic control. According to recent research, failing to administer as few as two doses weekly could increase HbA1C levels by as much as 0.4, thus elevating the risk of diabetes-related complications. The potential of the MiniMed Go™ to improve treatment adherence could profoundly influence patient outcomes.

Moreover, data from Medtronic’s previous Smart MDI system illustrates the potential effectiveness of these new features. Users who respond to over 75% of missed dose alerts within an hour achieve an average Time in Range (TIR) of 67.2%, significantly above the cohort average of 55.7%. Furthermore, proactive alerts for high blood sugar levels yield an even higher TIR of 71.5%. Que Dallara, the Executive Vice President and president of Medtronic Diabetes, underscores the importance of real-time alerts, stating that they are essential for improving clinical outcomes in diabetes management. As Medtronic proceeds with the gradual rollout of the MiniMed Go™, the promise of more effective diabetes management tools is poised to reshape patient experiences across Europe.

In addition to the launch, Medtronic's efforts reflect an ongoing commitment to innovation in diabetes care. As it integrates technology into treatment, the company not only addresses current challenges but also sets the groundwork for future advancements in diabetes management. With an increased focus on user experience and data connectivity, Medtronic aims to elevate the standard of care for individuals living with diabetes.

The introduction of the MiniMed Go™ system exemplifies Medtronic's proactive approach to enhancing diabetes management through advanced technology. By leveraging smart devices and data analytics, the company reinforces its position at the forefront of healthcare innovation, firmly placing patient empowerment and effective management at the heart of its mission.